Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTG 200 (Primary)
  • Indications Crohn's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PRISM; PRISM-SCARLET
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 07 Jan 2022 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: IAC completed review of futility analysis data & determined that futility criteria were met. As a result, Janssen made decision to stop trial immediately.
    • 01 Dec 2021 Status changed from recruiting to active, no longer recruiting.
    • 11 Nov 2021 This trial has been discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top